Betty Hamilton, MD

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia and myelodysplastic syndromes on allogeneic hematopoietic cell transplant outcomes and the adverse impact of TET2 mutations.